The transition of a low-grade, slow growing brain tumor to a lethal one can be delayed if neurosurgeons remove as much as possible soon after diagnosis, according to the results of a study led by UC San Francisco.
Jan 4, 2023
0
23
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free ...
Dec 8, 2022
0
6
Two new studies from researchers at Fred Hutchinson Cancer Center in Seattle reveal how bacteria infiltrate tumors and could be helping tumors progress and spread. The research team also showed that the different microbial ...
Nov 16, 2022
0
57
High levels of certain intestinal bacteria, like Fusobacterium nucleatum, can promote tumor progression in patients with colorectal cancer. Now, Japanese scientists have revealed a unique mechanism through which excessive ...
Nov 10, 2022
0
1
Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression and lower survival rates, according to recent Cleveland Clinic research.
Nov 8, 2022
0
36
A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free, a new study by UT Southwestern ...
Nov 8, 2022
0
54
In a recent University of Kentucky Markey Cancer Center clinical trial, patients with advanced cancer experienced improved outcomes when their treatments were directed by a molecular tumor board.
Sep 22, 2022
0
18
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of ...
Sep 13, 2022
0
20
A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported ...
Sep 11, 2022
0
24
The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of ...
Sep 8, 2022
0
34
